Opevesostat (ODM208) is the first-in-class, selective, nonsteroidal, oral CYP11A1 inhibitor. ODM208 exhibits a rapid, complete, durable, and reversible inhibition of the steroid hormone biosynthesis in an adrenocortical carcinoma cell model in vitro, in adult noncastrated male mice and dogs, and in patients with CRPC.